JonesTrading analyst Matthew Cross maintained a Buy rating on Aptose Biosciences (APTO) today and set a price target of $7. The company’s shares closed yesterday at $2.34.
According to TipRanks.com, Cross has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.0% and a 32.7% success rate. Cross covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Catalyst Biosciences Inc, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $6.33, which is a 170.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $6 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.20 and a one-year low of $1.57. Currently, Aptose Biosciences has an average volume of 421.7K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent.
